International leading innovative drug enterprise of immune antibody
Akeso Biology was founded by the national "Thousand Talents Plan" expert team in 2012 and is one of the most innovative antibody pharmaceutical enterprises in China.
In 2015, the company transferred the independently developed new monoclonal antibody drug AK107 to the global pharmaceutical giant MSD, with a transfer amount of US $200 million.
In August 2018, SciNova Fund invested 50 million yuan in Akeso Biology.
In June 2019, Akeso Biology and Chia Tai Tianqing Pharmaceutical established a joint venture to jointly develop the PD-1 antibody AK105 project and promote its registration, listing and commercialization.
In July 2019, the PD-1/VEGF bispecific antibody new drug AK112 developed by Akeso Company was approved by the US FDA for drug clinical trials (IND).
In July 2019, Akeso Biology and IQVIA, the world's leading medical service provider, announced deep strategic cooperation.
On April 24, 2020, Akeso Biology was listed in Hong Kong stock, code: 09926.HK.Morgan Stanley and JPMorgan Chase co sponsor.